Research and Projects
Identifying HIV Care Outcomes And Resilience Among Women Exposed to Partner Violence
This research is funded by the National Institutes of Health - R01 MH121991
The main purpose of this study is to understand how exposure to intimate partner violence (IPV) affects women’s abilities to self-manage their HIV on a daily basis (i.e., adhere to antiretroviral medication), engage in longitudinal HIV care, and achieve and sustain viral suppression. The project aims to build awareness of the IPV-health association and inform strategies/resources to promote resilience.
Project CHANGE: Comprehensive Housing and Addiction Management Network for Greater New Haven
This research is funded by the Substance Abuse and Mental Health Administration (SAMHSA) – TI080561
The primary aim of this service-oriented project is to expand and enhance the local implementation of a community infrastructure that integrates housing, behavioral health, and addiction treatment services for justice-involved men and women who experience co-occurring homelessness, psychiatric, and substance use disorders. By co-locating these services for the target population, we aim to improve access to health services, social support, housing, and recovery support services; facilitate reintegration into society and reduce recidivism among this highly vulnerable population. This project is in partnership with the Yale Community Health Care Van (CHCV) and Liberty Community Services.
Project OPTIONS: Developing and Testing the Effect of a Patient-Centered HIV Prevention Decision Aid on PrEP uptake for Women with Substance Use in Treatment Settings
This research is funded by a Doris Duke Charitable Foundation Clinical Scientist Development Award.
The overarching goal of this project is to facilitate HIV pre-exposure prophylaxis (PrEP) uptake among women who use drugs by elevating women’s awareness of PrEP and an appropriate perception of their personal HIV risk. We aim to do this in two ways: (1) by creating a patient-centered HIV prevention decision aid for women with substance use disorders entering treatment; and (2) to test the effect of the informed decision aid intervention on PrEP uptake among women with substance use disorders entering treatment. We hypothesize that compared to those receiving standard harm reduction information, women receiving the standard substance use decision aid will have increased PrEP uptake at 6 and 12 months post-intervention.
This research study is registered at ClinicalTrials.gov (NCT03651453)
- Oral presentation: Decision-Making about HIV Prevention among Women in Drug Treatment: Is PrEP Contextually Relevant? SGIM New England Regional Meeting. Boston, Massachusetts. November 2019. Accepted for Presentation.
- Impact of Motherhood Identity on Women’s Substance Use and Engagement in Treatment Across the Lifespan. International Women’s and Children’s Health and Gender (InWomen’s) Group. Hollywood, Florida. June 2020. Accepted for Presentation.
PrEP WAVE: Optimizing PrEP's Potential in Non-Clinical Settings: Development and Evaluation of a PrEP Decision Aid for Women Seeking Domestic Violence Services
This project is funded by a Pilot Project Award from the Center for Interdisciplinary Research on AIDS (CIRA).
This Type II hybrid effectiveness-implementation study seeks to adapt an existing PrEP decision aid to intimate partner violence (IPV)-exposed women seeking domestic violence (DV) services at two major Connecticut service agencies. This study will: provide support for a PrEP decision aid that addresses the HIV prevention needs of IPV-exposed women; use implementation science to increase PrEP uptake; include DV agencies in intervention development and implementation; and improve understanding of PrEP scale-up by addressing implementation factors in the community settings that serve IPV-exposed women.
Project+Pink: Evaluating and Improving HIV Outcomes in Community-based Women who Interface with the Criminal Justice System
This project was funded by the National Institute on Drug Use (NIDA)
Research data suggest that the experiences of women require a somewhat different intervention approach compared to men in order to be optimally efficacious for reducing HIV sex and drug-related risk-taking behaviors. This project aimed to fill in the gaps for sex-specific interventions among drug users and those involved in the criminal justice system by adapting and pilot testing the Holistic Health Recovery Program for women with HIV (HHRP+), a CDC evidence-based secondary HIV prevention intervention. This intervention served as a framework to optimize HIV treatment outcomes for women under correctional supervision.
MAK: Prisons, Drug Injection and the HIV Risk Environment in Kyrgyzstan
This research is supported by the National Institute on Drug Abuse (NIDA)
We propose to generate qualitative data from interviews with prisoners and prison staff and triangulate it with quantitative data from MATLINK within an analytical HIV risk environment framework which aims to: 1. Describe the individual-environment interactions that shape within-prison drug-related HIV risk practices and health expectations post-release; and 2. Measure how within-prison risk and other factors within the prison environment mediate engagement with OAT both within prison and after release.
Project EMPOWERING: Delivering HIV Pre-Exposure Prophylaxis to Networks of Justice-Involved Women
This research is supported by a Gilead Sciences Investigator-Sponsored Research Award
PrEP is transforming the landscape of HIV prevention but is understudied in women, particularly criminal justice (CJ) involved women. This research study has two central aims (1) To assess PrEP awareness, attitudes, and clinical eligibility among CJ-involved women and compare them across the CJ continuum; and (2) To evaluate the acceptability and feasibility of strategically delivering PrEP to CJ-involved women and members of their risk networks. We hypothesize that among those clinically eligible for PrEP, it will be feasible and acceptable to initiate PrEP among CJ-involved women and recruit members of their high-risk networks.This research study is registered at ClinicalTrials.gov (NCT03293290)